US Patent

US9149428 — Processes for making cyclic lipid implants for intraocular use

Formulation · Assigned to Allergan Inc · Expires 2026-12-19 · 1y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects processes for making biocompatible implants containing a cyclic lipid therapeutic agent for intraocular use.

USPTO Abstract

Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.

Drugs covered by this patent

Lumigan (BIMATOPROST)

Patent Metadata

Patent number: US9149428
Jurisdiction: US
Classification: Formulation
Expires: 2026-12-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Allergan Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.